PhoreMost completes $15M Series-A round to enter drug discovery
Investment to fund expansion of operations and progression of drug target pipeline
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has completed an £11m ($15m) Series-A investment round. The investment will be used to expand operations on the Babraham Research Campus and progress several novel drug targets from its next-generation “SITESEEKER®” phenotypic screening platform into first-in-class drug discovery programmes.
The new investment follows a successful validation phase, which saw PhoreMost grow from a Cambridge University spin-out in 2015 with early proof-of-concept data, to a technically and commercially validated enterprise in 2017. The Company’s SITESEEKER® platform can identify the best new therapeutic targets for any chosen disease setting and rapidly identify how to develop novel drugs to them, which has the potential to significantly increase the diversity and affordability of novel treatments for cancer and other unmet diseases. Using its platform, PhoreMost has built a proprietary novel target pipeline, signed two pharma collaboration deals, and spun-out a new company ‘NeoPhore’ to progress a novel target for cancer immunotherapy into the small-molecule development stage. The funding will enable PhoreMost to expand the range and depth of other proprietary targets into the drug discovery process.
The Series-A round was led by current investors Jonathan Milner, Amadeus Capital Partners, Cambridge Enterprise, and cornerstone Parkwalk Advisors, a London-based investor specialising in UK university generated IP. Morningside Ventures, a prolific backer of global biotech enterprises, is the principal new investor, with Dr Gerald Chan from Morningside joining the PhoreMost Board. Alastair Kilgour of Parkwalk also joins the Board.
Dr Chris Torrance CEO of PhoreMost, said: “We are thrilled to have the support of our existing investors and Morningside in enabling PhoreMost to move into its next exciting phase of growth. Their funding and shared vision is a key part of PhoreMost becoming a fully-fledged ‘ethical’ drug discovery company that aims to bring a greater diversity of therapies to patients, more quickly and at prices they can afford.”
Other news from the department business & finance
Most read news
More news from our other portals
Last viewed contents
How do molecular motors convert chemical energy in to mechanical work? - Researchers reveal structure and function of a complex micro machine
Student_National_Medical_Association
Pharming's C1 inhibitor product potentially effective in reducing complications following transplantation
Natural molecule could improve Parkinson's
Laboratory study: effect of antibodies against omicron variants BA.1 and BA.2 wears off quickly
Covid-19 can trigger diabetes - When SARS-CoV-2 infects beta cells, they produce less insulin and show signs of death
Spinifex to be acquired by Novartis - Australian pain drug innovation company sold to Novartis for US$200m plus milestone payments
New mechanism that leads to inflammation in rheumatoid arthritis discovered
